(Q38078179)

28 August 2017

1 reference

title

Systematic review of economic evaluation studies: are vaccination programs efficient in Spain? (English)

1 reference

28 August 2017

Anna García-Altés

1

1 reference

28 August 2017

language of work or name

English

0 references

publication date

29 January 2013

1 reference

28 August 2017

1 reference

28 August 2017

volume

31

1 reference

28 August 2017

issue

13

1 reference

28 August 2017

page(s)

1656-1665

1 reference

Relación en España entre la investigación sanitaria financiada por el Sistema Nacional de Salud y la carga de enfermedad en la comunidad

28 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Global progress in infectious disease control

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

During the 'decade of vaccines,' the lives of 6.4 million children valued at $231 billion could be saved

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Estimated economic benefits during the 'decade of vaccines' include treatment savings, gains in labor productivity

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

30 years of pharmaceutical cost-utility analyses: growth, diversity and methodological improvement

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Construcción de un filtro geográfico para la identificación en PubMed de estudios realizados en España

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Burden of disease and economic evaluation of healthcare interventions: are we investigating what really matters?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

[Cost-effectiveness of 23-valent antipneumococcical vaccination in Catalonia (Spain)]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-effectiveness of pneumococcal vaccination of older people: a study in 5 western European countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-effectiveness of pneumococcal vaccination for prevention of invasive pneumococcal disease in the elderly: an update for 10 Western European countries

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

A pharmacoeconomic evaluation of seven-valent pneumococcal conjugate vaccine in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

A cost benefit analysis of routine varicella vaccination in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-benefit and cost-effectiveness of the incorporation of the pneumococcal 7-valent conjugated vaccine in the routine vaccination schedule of Catalonia (Spain)

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-effectiveness analysis of pneumococcal vaccination in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-effectiveness of human papillomavirus vaccination and screening in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Burden of paediatric Rotavirus Gastroenteritis (RVGE) and potential benefits of a universal Rotavirus vaccination programme with a pentavalent vaccine in Spain.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Social and economic impact of chicken pox vaccine at 15 months of age. Castile and Leon, Spain, 2004

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Pharmacoeconomic assessment of implementing a universal PCV-13 vaccination programme in the Valencian public health system (Spain).

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

[Cost-effectiveness of varicella vaccination in Spanish adolescents]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Economic evaluation of varicella vaccination in Spain: results from a dynamic model

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-effectiveness analysis of inactivated virosomal subunit influenza vaccination in children aged 3-14 years from the provider and societal perspectives.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Economic benefits for the family of inactivated subunit virosomal influenza vaccination of healthy children aged 3-14 years during the annual health examination in private paediatric offices.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

[Efficiency of influenza vaccination in the working population in Spain]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

[Analysis of a economic model of a populational influenza immunization strategy in healthy employees]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

The cost effectiveness of influenza vaccination for adults aged 50 to 64 years: a model-based analysis for Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Vaccination against hepatitis B virus in Spain: a cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-Benefit Analysis of Hepatitis-B Vaccination: A Computerized Decision Model for Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Efficiency of the incorporation of the hepatitis A vaccine as a combined A+B vaccine to the hepatitis B vaccination programme of preadolescents in schools.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost effectiveness of hepatitis A virus immunisation in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Cost-Benefit Analysis of Haemophilus influenzae Type b Vaccination in Children in Spain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Effectiveness and economic analysis of the whole cell/recombinant B subunit (WC/rbs) inactivated oral cholera vaccine in the prevention of traveller's diarrhoea.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Mathematical modelling of respiratory syncytial virus (RSV): vaccination strategies and budget applications

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Twenty years of health care economic analysis in Spain: are we doing well?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

[Health promotion: a profitable investment? Economic efficiency of preventive interventions in Spain]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Health care CBA/CEA: an update on the growth and composition of the literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Health Care CBA and CEA from 1991 to 1996: An Updated Bibliography

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Costing and perspective in published cost-effectiveness analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

[A proposed guideline for economic evaluation of health technologies]

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

De la utilidad de los medicamentos al valor terapéutico añadido y a la relación coste-efectividad incremental

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

The improbable plunge. What facts refute reasons to expect that the effectiveness of HPV vaccination programs to prevent cervical cancer could be low?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Economic evaluations of massive HPV vaccination: within-study and between study variations in incremental cost per QALY gained.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Evolution of the health economics of cervical cancer vaccination

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Do we fully understand the economic value of vaccines?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

The role of cost-effectiveness in U.S. vaccination policy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

The value of vaccination: a global perspective

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

The future of immunisation policy, implementation, and financing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Addressing the vaccine confidence gap.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Bias in published cost effectiveness studies: systematic review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

A reappraisal of economic evaluation of pharmaceuticals. Science or marketing?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Conflict of interest in industry-sponsored economic evaluations: real or imagined?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2013.01.029

10.1016/J.VACCINE.2013.01.029

7 January 2021

Identifiers

DOI

1 reference

28 August 2017

1 reference